Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1

Status

Completed 21Recruiting 10Not yet recruiting 4Active not recruiting 4Unknown 3Terminated 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2

Conditions

Colorectal Neoplasms 28Stomach Neoplasms 21Pancreatic Neoplasms 14Colonic Neoplasms 14Rectal Neoplasms 9Esophageal Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7Adenocarcinoma Of Esophagus 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Cholangiocarcinoma 4Adenocarcinoma 4Ovarian Neoplasms 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Follicular 2Hepatoblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable Colorectal Cancer 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Cancer 1Skin Neoplasms 1Recurrence 1

Interventions

pembrolizumab 4Oxaliplatin 4zolbetuximab 2camrelizumab 2apatinib 2S 1 (combination) 2Paclitaxel 2Nivolumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1tepotinib 1relugolix 1regorafenib 1lenvatinib 1durvalumab 1dabrafenib 1cemiplimab 1cabazitaxel 1alpha-2'-deoxythioguanosine 1X-Rays 1Vinorelbine 1Trifluridine 1Surveys and Questionnaires 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma × Oxaliplatin × Clear all
NCT03504397 2026-05-04

Spotlight

Astellas Pharma Inc

Phase 3 Active not recruiting
565 enrolled 63 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-04-17

GLOW

Astellas Pharma Inc

Phase 3 Active not recruiting
507 enrolled 65 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Ruijin Hospital

Phase 2 Active not recruiting
80 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Ruijin Hospital

Phase 2/3 Active not recruiting
580 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡